1. Gilmore RL. Seizures associated with non-neurologic medical conditions. In E Wyllie (ed), The Treatment of Epilepsy: Principles and Practice. Baltimore: Williams & Wilkins, 1996;654-665.

2. Garcia-Alvarez M, Nordli DR, De Vivo DC. Inherited metabolic disorders. In J Engel, TA Pedley (eds), Epilepsy: a Comprehensive Textbook. Philadelphia: Lippincott–Raven, 1998;2547-2562.

3. Messing RO, Simon RP. Seizures as a manifestation of systemic disease. Neurol Clin 1986;4:563-584.

4. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In AS Fauci, E Braunwald, KJ Isselbacher et al. (eds), Harrison's Principles of Internal Medicine (14th ed). New York: McGraw-Hill, 1998;265-277.

5. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976;10:25-37.

6. Siegel AJ, Baldessarini RJ, Klepser MB, McDonald JC. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Harv Rev Psychiatry 1998;6:190-200.

7. Gowrishankar M, Lin SH, Mallie JP, et al. Acute hyponatremia in the perioperative period: insights into its pathophysiology and recommendations for management. Clin Nephrol 1998;50:352-360.

8. Kokko JP. Fluids and Electrolytes. In L Goldman, JC Bennett (eds), Cecil Textbook of Medicine (21st ed). Philadelphia: Saunders, 2000;540-567.

9. Maesaka JK. An expanded view of SIADH, hyponatremia, and hypouricemia. Clin Nephrol 1996;46:79-83.

10. Riggs JE. Neurologic manifestations of fluid and electrolyte disturbances. Neurol Clin 1989;7:509-523.

11. Daggett P, Deanfield J, Moss F. Neurological aspects of hyponatraemia. Postgrad Med J 1982;58:737-740.

12. Hojer J. Management of symptomatic hyponatraemia: dependence on the duration of development. J Intern Med 1994;235:497-501.

13. Farrar HC, Chande VT, Fitzpatrick DF, Shema SJ. Hyponatremia as the cause of seizures in infants: a retrospective analysis of incidence, severity, and clinical predictors. Ann Emerg Med 1995;26:42-48.

14. Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986;314:1529-1535.

15. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med 1997;126:57-62.

16. Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases. Ann Intern Med 1987;107:656-664.

17. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986;314:1535-1542.

18. Sarnaik AP, Meert K, Hackbarth R, Fleischmann L. Management of hyponatremic seizures in children with hypertonic saline: a safe and effective strategy. Crit Care Med 1991;19:758-762.

19. Ellis SJ. Severe hyponatraemia: complications and treatment. QJM 1995;88:905-909.

20. Ayus JC, Arieff AI. Abnormalities of water metabolism in the elderly. Semin Nephrol 1996;16:277-288.

21. Rose BD. Clinical Physiology of Acid-Base and Electrolyte Disorders (4th ed). New York: McGraw-Hill, 1994.

22. McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med 1995;333:1260-1266.

23. Daggett P, Deanfield J, Moss F, Reynolds D. Severe hypernatraemia in adults. BMJ 1979;1:1177-1180.

24. Meadow R. Non-accidental salt poisoning. Arch Dis Child 1993;68:448-452.

25. Lien YH, Shapiro JI, Chan L. Effects of hypernatremia on organic brain osmoles. J Clin Invest 1990;85:1427-1435.

26. Foster DW, Rubenstein AH. Hypoglycemia. In AS Fauci, E Braunwald, KJ Isselbacher et al. (eds), Harrison's Principles of Internal Medicine (14th ed). New York: McGraw-Hill, 1998;2081-2087.

27. Malouf R, Brust JC. Hypoglycemia: causes, neurological manifestations, and outcome. Ann Neurol 1985;17:421-430.

28. Polonsky KS. A practical approach to fasting hypoglycemia. N Engl J Med 1992;326:1020-1021.

29. Rizza RA, Service FJ. Hypoglycemia/pancreatic islet cell disorders. In L Goldman, JC Bennett (eds), Cecil Textbook of Medicine (21st ed). Philadelphia: Saunders, 2000;1285-1292.

30. Arieff AI, Carroll HJ. Nonketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid-base balance, plasma-cerebrospinal fluid equilibria and the effects of therapy in 37 cases. Medicine (Baltimore) 1972;51:73-94.

31. Morres CA, Dire DJ. Movement disorders as a manifestation of nonketotic hyperglycemia. J Emerg Med 1989;7:359-364.

32. Guisado R, Arieff AI. Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain. Metabolism 1975;24:665-679.

33. Venna N, Sabin TD. Tonic focal seizures in nonketotic hyperglycemia of diabetes mellitus. Arch Neurol 1981;38:512-514.

34. Brick JF, Gutrecht JA, Ringel RA. Reflex epilepsy and nonketotic hyperglycemia in the elderly: a specific neuroendocrine syndrome. Neurology 1989;39:394-399.

35. Singh BM, Strobos RJ. Epilepsia partialis continua associated with nonketotic hyperglycemia: clinical and biochemical profile of 21 patients. Ann Neurol 1980;8:155-160.

36. Aquino A, Gabor AJ. Movement-induced seizures in nonketotic hyperglycemia. Neurology 1980;30:600-604.

37. Hennis A, Corbin D, Fraser H. Focal seizures and nonketotic hyperglycaemia. J Neurol Neurosurg Psychiatry 1992;55:195-197.

38. Desai TK, Carlson RW, Geheb MA. Hypocalcemia and hypophosphatemia in acutely ill patients. Crit Care Clin 1987;3:927-941.

39. Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med 1988;84:209-214.

40. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363-375.

41. Fonseca OA, Calverley JR. Neurological manifestations of hypoparathyroidism. Arch Intern Med 1967;120:202-206.

42. Gupta MM. Medical emergencies associated with disorders of calcium homeostasis. J Assoc Physicians India 1989;37:629-631.

43. Macefield G, Burke D. Paraesthesiae and tetany induced by voluntary hyperventilation. Increased excitability of human cutaneous and motor axons. Brain 1991;114:527-540.

44. Swash M, Rowan AJ. Electroencephalographic criteria of hypocalcemia and hypercalcemia. Arch Neurol 1972;26:218-228.

45. Ryzen E, Rude RK. Low intracellular magnesium in patients with acute pancreatitis and hypocalcemia. West J Med 1990;152:145-148.

46. Connor TB, Toskes P, Mahaffey J, et al. Parathyroid function during chronic magnesium deficiency. Johns Hopkins Med J 1972;131:100-117.

47. Chase LR, Slatopolsky E. Secretion and metabolic efficacy of parathyroid hormone in patients with severe hypomagnesemia. J Clin Endocrinol Metab 1974;38:363-371.

48. Agus ZS. Hypomagnesemia. J Am Soc Nephrol 1999;10:1616-1622.

49. al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 1994;24:737-752.

50. Booth BE, Johanson A. Hypomagnesemia due to renal tubular defect in reabsorption of magnesium. J Pediatr 1974;85:350-354.

51. Wong ET, Rude RK, Singer FR, Shaw ST Jr. A high prevalence of hypomagnesemia and hypermagnesemia in hospitalized patients. Am J Clin Pathol 1983;79:348-352.

52. Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia. Requested vs. routine. JAMA 1990;263:3063-3064.

53. Ryzen E. Magnesium homeostasis in critically ill patients. Magnesium 1989;8:201-212.

54. Chernow B, Bamberger S, Stoiko M, et al. Hypomagnesemia in patients in postoperative intensive care. Chest 1989;95:391-397.

55. See AC, Soo KC. Hypocalcaemia following thyroidectomy for thyrotoxicosis. Br J Surg 1997;84:95-97.

56. Yamashita H, Noguchi S, Murakami T, et al. Seasonal changes in calcium homeostasis affect the incidence of postoperative tetany in patients with Graves' disease. Surgery 2000;127:377-382.

57. Hossain M. Neurological and psychiatric manifestations in idiopathic hypoparathyroidism: response to treatment. J Neurol Neurosurg Psychiatry 1970;33:153-156.

58. Soffer D, Licht A, Yaar I, Abramsky O. Paroxysmal choreoathetosis as a presenting symptom in idiopathic hypoparathyroidism. J Neurol Neurosurg Psychiatry 1977;40:692-694.

59. Rubenstein A, Brust JC. Parkinsonian syndrome as complication of post-thyroidectomy hypoparathyroidism. N Y State J Med 1974;74:2029-2030.

60. Frensilli JA, Stoner RE, Hinrichs EH. Dental changes of idiopathic hypoparathyroidism: report of three cases. J Oral Surg 1971;29:727-731.

61. Jensen SB, Illum F, Dupont E. Nature and frequency of dental changes in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Scand J Dent Res 1981;89:26-37.

62. Illum F, Dupont E. Prevalences of CT-detected calcification in the basal ganglia in idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neuroradiology 1985;27:32-37.

63. Muenter MD, Whisnant JP. Basal ganglia calcification, hypoparathyroidism, and extrapyramidal motor manifestations. Neurology 1968;18:1075-1083.

64. Schimke RN. Hyperthyroidism. The clinical spectrum. Postgrad Med J 1992;91:229-236.

65. Ahronheim JC. Hyperthyroid chorea in an elderly woman associated with sole elevation of T3. J Am Geriatr Soc 1988;36:242-244.

66. Su YH, Izumi T, Kitsu M, Fukuyama Y. Seizure threshold in juvenile myoclonic epilepsy with Graves' disease. Epilepsia 1993;34:488-492.

67. Sundaram MB, Hill A, Lowry N. Thyroxine-induced petit mal status epilepticus. Neurology 1985;35:1792-1793.

68. Jabbari B, Huott AD. Seizures in thyrotoxicosis. Epilepsia 1980;21:91-96.

69. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000;105:e10.

70. Paine RS. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic acidosis). Pediatrics 1969;19:1007-1011.

71. Lutcke A, Bickel H. Electroencephalographic manifestations of cerebral attacks and intellectual development in phenylketonuria. Electroencephalogr Clin Neurophysiol 1969;27:625.

72. McGovern MM, Desnick RJ. Lysosomal Storage Diseases. In L Goldman, JC Bennett (eds), Cecil Textbook of Medicine (21st ed). Philadelphia: Saunders, 2000;1104-1107.

73. Higgins JJ, Patterson MC, Dambrosia JM, et al. A clinical staging classification for type C Niemann-Pick disease. Neurology 1992;42:2286-2290.

74. Andersson HC, Shapira E. The Mucopolysacchari- doses. In L Goldman, JC Bennett (eds), Cecil Textbook of Medicine (21st ed). Philadelphia: Saunders, 2000;1116-1118.

75. Anderson KE. The Porphyrias. In L Goldman, JC Bennett (eds), Cecil Textbook of Medicine (21st ed). Philadelphia: Saunders, 2000;1123-1130.

76. Bloomer JR. The hepatic porphyrias: pathogenesis, manifestations, and management. Gastroenterology 1976;71:689-701.

77. Pierach CA, Edwards PS. Neurotoxicity of delta-aminolevulinic acid and porphobilinogen. Exp Neurol 1978;62:810-814.

78. Bloomer JR, Bonkovsky HL. The porphyrias. Dis Mon 1989;35:1-54.

79. Mustajoki P, Kauppinen R, Lannfelt L, et al. Frequency of low erythrocyte porphobilinogen deaminase activity in Finland. J Intern Med 1992;231:389-395.

80. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Intern Med 1974;83:851-864.

81. Burgovne K, Swartz R, Ananth J. Porphyria: reexamination of psychiatric implications. Psychother Psycho- som 1995;64:121-130.

82. Tishler PV, Woodward B, O'Connor J, et al. High prevalence of intermittent acute porphyria in a psychiatric patient population. Am J Psychiatry 1985;142:1430-1436.

83. Kaplan PW, Lewis DV. Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature. J Child Neurol 1986;1:38-45.

84. Birchfield RI, Cowger ML. Acute intermittent porphyria with seizures. Anticonvulsant medication-induced metabolic changes. Am J Dis Child 1966;112:561-565.

85. Reynolds NC, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology 1981;31:480-484.

86. Bylesjo I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia 1996;37:230-235.

87. Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 1998;18:57-65.

88. Kalman DR, Bonkovsky HL. Management of acute attacks in the porphyrias. Clin Dermatol 1998;16:299-306.

89. Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Semin Liver Dis 1998;18:53-55.

90. Sergay SM. Management of neurologic exacerbations of hepatic porphyria. Med Clin North Am 1979;63:453-463.

91. Hahn M, Gildemeister OS, Krauss GL, et al. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 1997;49:97-106.

92. Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995;45:594-595.

93. Lambrecht RW, Gildemeister OS, Williams A, et al. Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation: implications for clinical porphyria. Biochem Pharmacol 1999;58:887-896.

94. Lambrecht RW, Gildemeister OS, Pepe JA, et al. Effects of antidepressants and benzodiazepine-type anxiolytic agents on hepatic porphyrin accumulation in primary cultures of chick embryo liver cells. J Pharmacol Exp Ther 1999;291:1150-1155.

95. Wijdicks EF, Sharbrough FW. New-onset seizures in critically ill patients. Neurology 1993;43:1042-1044.

96.Hopkins A. The causes of epilepsy, the risk factors for epilepsy and the precipitation of seizures. In: Hopkins A, Shorvon S, Cascino G, (eds). Epilepsy. Second Edition. London: Chapman & Hall Medical, 1995, 59-85.

 

Adapted from: Schachter SC and Lopez MR. Metabolic disorders. In: Ettinger AB and Devinsky O, eds. Managing epilepsy and co-existing disorders. Boston: Butterworth-Heinemann; 2002;195-208.
With permission from Elsevier (www.elsevier.com).

I<